Citation
Feng, Yunlu, et al. "Prophylactic Rectal Indomethacin May Be Ineffective for Preventing Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis in General Patients: a Meta-analysis." Digestive Endoscopy : Official Journal of the Japan Gastroenterological Endoscopy Society, vol. 29, no. 3, 2017, pp. 272-280.
Feng Y, Navaneethan U, Zhu X, et al. Prophylactic rectal indomethacin may be ineffective for preventing post-endoscopic retrograde cholangiopancreatography pancreatitis in general patients: A meta-analysis. Dig Endosc. 2017;29(3):272-280.
Feng, Y., Navaneethan, U., Zhu, X., Varadarajulu, S., Schwartz, I., Hawes, R., Hasan, M., & Yang, A. (2017). Prophylactic rectal indomethacin may be ineffective for preventing post-endoscopic retrograde cholangiopancreatography pancreatitis in general patients: A meta-analysis. Digestive Endoscopy : Official Journal of the Japan Gastroenterological Endoscopy Society, 29(3), 272-280. https://doi.org/10.1111/den.12779
Feng Y, et al. Prophylactic Rectal Indomethacin May Be Ineffective for Preventing Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis in General Patients: a Meta-analysis. Dig Endosc. 2017;29(3):272-280. PubMed PMID: 27914176.
TY - JOUR
T1 - Prophylactic rectal indomethacin may be ineffective for preventing post-endoscopic retrograde cholangiopancreatography pancreatitis in general patients: A meta-analysis.
AU - Feng,Yunlu,
AU - Navaneethan,Udayakumar,
AU - Zhu,Xiang,
AU - Varadarajulu,Shyam,
AU - Schwartz,Ingrid,
AU - Hawes,Robert,
AU - Hasan,Muhammad,
AU - Yang,Aiming,
Y1 - 2017/01/03/
PY - 2016/09/30/received
PY - 2016/11/28/accepted
PY - 2016/12/4/pubmed
PY - 2018/4/5/medline
PY - 2016/12/4/entrez
KW - endoscopic retrograde cholangiopancreatography (ERCP)
KW - indomethacin
KW - meta-analysis
KW - pancreatitis
KW - prevention
SP - 272
EP - 280
JF - Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
JO - Dig Endosc
VL - 29
IS - 3
N2 - BACKGROUND AND AIM: Efficacy of prophylactic indomethacin for prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) in general patients remains controversial. To address this, we conducted a meta-analysis of clinical trials specifically on rectal indomethacin in prevention of PEP in consecutive patients undergoing ERCP. METHODS: We searched MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials databases to identify randomized, double-blind, controlled clinical trials on rectal indomethacin in the prevention of PEP in consecutive patients undergoing ERCP. Primary outcome was the overall rate of PEP. Secondary outcomes were the overall rates of moderate to severe PEP and mild PEP. RESULTS: Six studies, with a total of 2473 patients, were included. Overall rate of PEP was 7% (95% CI, 6-9%). No statistical difference was observed in overall rates of PEP (OR, 0.67; 95% CI, 0.46-1.00, P = 0.050) and, additionally, rates of moderate to severe (OR, 0.66; 95% CI, 0.28-1.56, P = 0.345) or mild (OR, 0.71; 95% CI, 0.45-1.10, P = 0.127) PEP between indomethacin and placebo. CONCLUSION: In a contemporary meta-analysis of available randomized controlled trials of consecutive patients undergoing ERCP, rectal indomethacin did not show significant prevention effect of post-ERCP pancreatitis.
SN - 1443-1661
UR - https://www.unboundmedicine.com/medline/citation/27914176/Prophylactic_rectal_indomethacin_may_be_ineffective_for_preventing_post_endoscopic_retrograde_cholangiopancreatography_pancreatitis_in_general_patients:_A_meta_analysis_
L2 - https://doi.org/10.1111/den.12779
DB - PRIME
DP - Unbound Medicine
ER -
